Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Earnings Data
Report Date
Mar 26, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.01Last Year’s EPS
-0.72Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in drug development and clinical progress, along with strong financial positioning and strategic expansions in clinic operations. However, there were challenges such as increased operational losses and limited initial revenue. Despite these challenges, the overall sentiment is optimistic due to the transformative progress and potential for substantial growth.Company Guidance
Transformative Progress and Drug Approvals
Advanced programs with drug approval applications in process for KETAFREE, NRX-100, and NRX-101. Expanded NRX-101 pipeline and closed on multiple acquisition targets for a network of interventional psychiatric clinics HOPE Therapeutics.
Positive Clinical Data
Real-world data showed an 87% treatment response and 72% remission from severe depression following a single day of treatment with TMS and low-dose D-cycloserine.
Revenue Generation and Clinic Expansion
Initiated revenue generation upon closing of acquisition of Dura Medical clinics. Plan to grow from 2 to 6 or more clinics by year-end with anticipated strong revenue growth.
Financial Stability and Investor Support
Stronger balance sheet with $10.3 million in cash and cash equivalents. Secured operating capital sufficient to fund operations through 2026.
Innovative Treatment Protocols
Launch of 1-day TMS treatment for severe depression using the ONE-D protocol in Florida.
NRXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NRXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 17, 2025 | $2.49 | $2.11 | -15.26% |
Aug 18, 2025 | $2.76 | $2.50 | -9.42% |
May 15, 2025 | $2.40 | $2.45 | +2.08% |
Mar 17, 2025 | $2.35 | $2.05 | -12.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NRX Pharmaceuticals (NRXP) report earnings?
NRX Pharmaceuticals (NRXP) is schdueled to report earning on Mar 26, 2026, Before Open (Confirmed).
What is NRX Pharmaceuticals (NRXP) earnings time?
NRX Pharmaceuticals (NRXP) earnings time is at Mar 26, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXP EPS forecast?
NRXP EPS forecast for the fiscal quarter 2025 (Q4) is 0.01.